Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carrelizumab combined with chemotherapy and apatinib in the first-line treatment of extensive-stage small cell lung cancer:a exploratory research

X
Trial Profile

Carrelizumab combined with chemotherapy and apatinib in the first-line treatment of extensive-stage small cell lung cancer:a exploratory research

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Camrelizumab (Primary) ; Rivoceranib (Primary) ; Antineoplastics; Etoposide
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Jun 2024 Status changed from not yet recruiting to recruiting, according to Results presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Jun 2024 Results (Up to January 24, 2024, n=31) assessing effectiveness and safety of camrelizumab combined with chemotherapy followed by maintenance camrelizumab and apatinib in the first-line treatment of ES-SCLC, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 03 Dec 2020 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top